Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Final clinical results of N-803 BCG Unresponsive NMIBC Trial

<< Previous

Bullboard Posts

Next >>

Post by Eoganachton May 14, 2022 10:00pm

451 Views

Post# 34684464

Final clinical results of N-803 BCG Unresponsive NMIBC Trial

were presented at the AUA2022 yesterday, Friday, May 13. We already knew the results - Cohort A (83 patients with CIS) achieved - 71% CR at any time - 36% CR at 2 years. Cohort B (77 patients with papillary disease) achieved a disease-free survival rate of 57% at 12 months and 48% at 24 months.

Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas